Total medical devices industry private equity deals in Q2 2019 worth $263.84m were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 82.4% over the previous quarter and a drop of 87.8% when compared with the last four-quarter average, which stood at $2.17bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $211.19m. At the country level, the US topped the list in terms of deal value at $211.19m.
In terms of volumes, North America emerged as the top region for medical devices industry private equity deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of private equity deals activity in Q2 2019 was the US with 13 deals, followed by the UK with four and Belgium with one.
In 2019, as of the end of Q2 2019, medical devices private equity deals worth $1.76bn were announced globally, marking a decrease of 79.03% year on year.
Medical devices industry private equity deals in Q2 2019: Top deals
The top five medical devices industry private equity deals accounted for 93.3% of the overall value during Q2 2019.
The combined value of the top five medical devices industry private equity deals stood at $246.2m, against the overall value of $263.84m recorded for the quarter. The top announced medical devices industry private equity deal tracked by GlobalData in Q2 2019 was Oberland Capital Management’s $100m private equity deal with NorthStar Medical Radioisotopes.
In second place was the $55m private equity deal with CardioFocus by Kennedy Lewis Investment Management and in third place was Delos Capital, Greenspring Associates, New Enterprise Associates, Quadrille Capital and Questa Capital Management’s $52m private equity deal with Intrinsic Therapeutics.
The $29.9m private equity deal with Medtrade Products by Tikehau Capital and Somerset Indus Capital Partners’ private equity deal with GenWorks Health for $9.3m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.